PedAM
Pediatric Disease Annotations & Medicines
| diabetes insipidus | ||||
| Disease ID | 261 |
|---|---|
| Disease | diabetes insipidus |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:49) C2712335 | dehydration C2697310 | sarcoidosis C2003861 | flushing C1879280 | angiocentric t-cell lymphoma C1863767 | m syndrome C1849156 | spastic ataxia C1839611 | n syndrome C1546654 | granuloma C1546533 | abscess C0878683 | panhypopituitarism C0752244 | rathke's cleft cyst C0595978 | idiopathic megacolon C0346300 | carcinoma of the pituitary gland C0271650 | glucose intolerance C0242342 | sheehan's syndrome C0234428 | disturbances of consciousness C0232826 | antidiuresis C0149925 | small cell lung cancer C0085602 | polydipsia C0043410 | pseudotuberculosis C0043325 | xanthomatosis C0041327 | pulmonary tuberculosis C0040034 | thrombocytopenia C0036421 | systemic sclerosis C0034065 | pulmonary embolism C0032617 | polyuria C0032019 | tumor of the pituitary gland C0029464 | osteosclerosis C0026848 | myopathy C0025193 | melancholia C0024796 | marfan's syndrome C0024299 | malignant lymphoma C0023787 | lipodystrophy C0023487 | acute promyelocytic leukemia C0023381 | histiocytosis x C0023138 | laurence-moon-biedl syndrome C0020635 | hypopituitarism C0020615 | hypoglycemia C0020550 | hyperthyroidism C0020428 | hyperaldosteronism C0020295 | hydronephrosis C0019621 | langerhans cell histiocytosis C0019618 | histiocytosis C0015300 | exophthalmos C0014130 | endocrinopathy C0011849 | diabetes mellitus C0009492 | compartment syndrome C0005683 | bladder stones C0001403 | addison's disease |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:10) C0032617 | polyuria | 12 C0085602 | polydipsia | 8 C0242343 | panhypopituitarism | 4 C0019621 | langerhans cell histiocytosis | 4 C0019618 | histiocytosis | 4 C0020635 | hypopituitarism | 2 C0011175 | dehydration | 2 C0242342 | sheehan's syndrome | 1 C1839611 | n syndrome | 1 C0018188 | granuloma | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0011848 | amiloride | D000584 | 2609-46-3 | diabetes insipidus | MESH:D003919 | therapeutic | 12680486 | ||
| C0011848 | haloperidol | D006220 | 52-86-8 | diabetes insipidus | MESH:D003919 | marker/mechanism | 5511121 | ||
| C0011848 | morphine | D009020 | 57-27-2 | diabetes insipidus | MESH:D003919 | therapeutic | 6258694 | ||
| C0011848 | ofloxacin | D015242 | 82419-36-1 | diabetes insipidus | MESH:D003919 | marker/mechanism | 11546701 | ||
| C0011848 | olanzapine | C076029 | 132539-06-1 | diabetes insipidus | MESH:D003919 | marker/mechanism | 15169711 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003919 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D003919 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
| MESH:D003919 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D003919 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003919 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D003919 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D003919 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |
| MESH:D003919 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |